Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Stoke Therapeutics Inc STOK

Healthcare Biotechnology
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:STOK)

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Business Wire 16 hours ago

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Business Wire 2 days ago

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Business Wire November 5, 2024

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Business Wire September 10, 2024

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Business Wire September 4, 2024

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Business Wire September 3, 2024

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Business Wire September 3, 2024

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire August 16, 2024

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Business Wire August 7, 2024
View More News ››

Opinion & Analysis (NDAQ:STOK)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:STOK)

Stoke Therapeutics Announces Plans to Present New Data that

NEWS: $STOK Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying...
whytestocks - 2 days ago

Stoke Therapeutics, Inc. (NASDAQ:STOK): Restoring Protein Ex

http://beyondspx.com/2024/08/01/stoke-therapeutics-inc-nasdaqstok-restoring-protein-expression-with-rna-therapeutics/
MikeTester - August 2, 2024

Where are the Opportunities in (STOK)

Just In: $STOK Where are the Opportunities in (STOK)2024-04-17 00:46:00 ET Stock Traders Daily has produced this trading report using a...
whytestocks - April 17, 2024

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021

watching this one for

an entry point price of around $19 per share is a much better price for me.
coolfooldumbguy - June 19, 2019
View more Bullboard ››

Coppernico Metals Inc.

Coppernico Metals Inc.

Coppernico is a mineral exploration company focused on creating value for shareholders and stakeholders through diligent ...
View More »